About this Research Topic
In the last years, next generation technology has progressively revolutionized clinical and research approaches either to solid or haematological cancers. Thanks to such an unprecedented resolution, scientists are currently able to comprehensively characterize several genomic and transcriptomic aspects of the cancer cell, with both diagnostic and prognostic relevance. Recent studies have proposed different genomic classifiers to correctly stratify distinct tumor entities as well as novel genetic drivers involved in cancer progression and/or resistance to current therapies. Our appreciation of the transcriptome complexity and of the role of small, long and circular RNAs in disease mechanisms is continuously increasing, expanding the repertoire of potentially druggable targets.
Indeed, several relevant and fascinating challenges are about to be addressed in the coming years: identifying the functional and biological significance of the driving genetic events; translating fundamental science into daily diagnostic clinical practice; finding novel prognostic markers and therapeutic targets to ultimately implement precise, effective and cost-saving therapies for patients with leukemia or lymphoma tumors.
This Research Topic is aimed at collecting the latest advances from outstanding researchers investigating genomics study in lymphoid malignancies. We welcome submission of Original Research and Review manuscripts dedicated to all of the genomics aspects of lymphoproliferative disease with a focus on, but not limited to, the following topics:
1) Mechanisms involved in lymphoproliferative disease pathogenesis and progression;
2) Tumor stratification;
3) Innovative therapeutic approaches;
4) Prognostic markers.
Keywords: next generation sequencing, lymphoproliferative disease, multiple myeloma, genomic, gene expression
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.